Baiji Shenzhou has obtained the exclusive global interest in the new coronavirus and antibodies of Danshu Bio.

Beijing time on August 27, 2020, Baiji Shenzhou (NASDAQ: BGNE; Hong Kong Stock Exchange code: 06160) and Beijing Danshu Biopharmaceutical Co., Ltd. today announced that the two sides have signed an exclusive licensing agreement, Baiji Shenzhou will develop, produce and commercialize Danshu Bio in the research of new crown virus and antibodies, including DXP-593 and DXP-604.
in preclinical studies, Dansor biology used high-flung single-cell sequencing techniques to screen several powerful and new coronavirus antibodies from blood samples recovered from neocyto pneumonia.
In accordance with the terms of the agreement, Danshu Bio has authorized Baiji Shenzhou to have exclusive development, production and commercialization rights for its preclinical candidate drugs DXP-593, DXP-604 and other anti-new crown and antibodies outside Greater China.
plans to develop one or more drug candidates worldwide outside of Greater China, and Danshu Bio will retain the rights in Greater China.
will receive a down payment and will be eligible for payment upon reaching the registration and commercialization milestones.
addition, Danshu Bio will be eligible for a double-digit sales tiered royalty for future products.
A randomized, double-blind, placebo-controlled Phase 1 clinical trial is expected to start in Australia in September, with up to 30 healthy subjects in the group, while phase 1/2 clinical trials to be conducted in several countries will be launched by early October in patients with mild to moderate new coronary pneumonia.
information about the two clinical trials will be published on clinicaltrials.gov.
: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Retrieved 2020-08-27, from.